A Study of NEOK002 in People With Solid Tumor Cancer

Full Title

A Phase 1 Dose Escalation and Expansion Study of NEOK002, an EGFR and MUC1 Targeting Bispecific Antibody-Drug Conjugate in Participants with Select Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Julia Blanter’s office at 646-888-5109.

Protocol
26-232
Phase
Phase I (phase 1)
Investigator
Julia Blanter
Co-Investigators
Adam J. Schoenfeld
Diseases
Colorectal Cancer
Lung Cancer › Lung Cancer, Non-Small Cell
Solid Tumors
Upper Gastrointestinal › Esophageal Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07612189
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description